{"filings":[{"id":94676,"accession_number":"0001654954-26-004419","cik":1684144,"company_name":"Zomedica Corp.","ticker":"ZOMDF","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zomedica Q1 revenue record $8.8M, up 35% YoY; net loss narrows to $4.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record Q1 revenue $8.8M, up 35% from $6.5M in Q1 2025; 21st straight quarter of YoY growth.","Diagnostics segment revenue $1.0M, +73% YoY; Therapeutic Devices $5.8M flat; Development Services $2.0M.","Net loss $4.5M vs $63.8M in prior year which included $55.8M impairment; Adjusted EBITDA loss improved 58% to $2.4M.","Cash burn reduced 15% to $5.7M; liquidity $47.5M as of March 31, 2026.","Launched TRUVIEW AI telepathology platform and announced collaboration with Boehringer Ingelheim for equine PPID testing."],"consensus_eps_estimate":null,"consensus_eps_actual":0.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":8799000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":101670000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107232,"accession_number":"0001654954-26-002304","cik":1684144,"company_name":"Zomedica Corp.","ticker":"ZOMDF","form_type":"8-K","filed_at":"2026-03-16T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zomedica reports record Q4 revenue $10.5M, full-year revenue $32.0M (+17% YoY)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $10.5M (+33% YoY); full year $32.0M (+17%). Record 20th straight YoY increase.","Gross margin 68% for year; Q4 69% best quarter. Adjusted EBITDA loss improved to $17.1M from $20.2M.","Cash burn reduced to $18.1M for year, $1.1M in Q4; cash/securities $53.3M.","Consumable revenue grew 16% to $20.7M; Development Services segment contributed $3.1M.","Net loss $81.9M includes $55.8M non-cash impairment; operating expenses ex-impairment down 7%."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":101670000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123570,"accession_number":"0001654954-25-012575","cik":1684144,"company_name":"Zomedica Corp.","ticker":"ZOMDF","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zomedica Q3 2025 revenue $8.1M (+16% YoY); net loss narrows to $6.1M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $8.1M, up 16% YoY; gross margin 67%; Diagnostics segment grew 51%.","Net loss $6.1M (down 9% YoY); adjusted EBITDA loss $3.9M.","Cash and securities $54.4M; operating expenses reduced $0.5M in Q3.","New Development Services segment generated $0.7M revenue in first quarter.","Record revenue for 19th straight quarter; new distribution agreements in UK, Netherlands, Canada."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":21559000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":101670000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140247,"accession_number":"0001654954-25-009136","cik":1684144,"company_name":"Zomedica Corp.","ticker":"ZOMDF","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zomedica Q2 revenue up 14% to $7M; Diagnostics segment jumps 86%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $7.0M, up 14% YoY; gross margin 67%, consistent with prior period.","Diagnostics segment revenue $0.8M (+86%), driven by TRUFORMA platform adoption.","Net loss $7.4M vs $23.9M (including $16M impairment) in Q2 2024; Adj. EBITDA loss $5.5M.","Operating expenses down $0.7M excluding impairment; liquidity $59.1M.","Record 18th consecutive quarter of YoY revenue growth; consumable sales up 21%."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":13464000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":101670000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157905,"accession_number":"0001654954-25-006839","cik":1684144,"company_name":"Zomedica Corp.","ticker":"ZOMDF","form_type":"8-K","filed_at":"2025-06-11T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Zomedica shareholders reject advisory vote on executive compensation at 2025 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Advisory vote on NEO compensation failed: 56.7M for, 82.4M against, 32.3M abstain.","All eight director nominees elected; Larry Heaton received lowest support (85.3M for, 86.1M against).","Ratification of Grant Thornton LLP as auditor for 2025 approved with 310.6M votes for.","Meeting held June 10, 2025; results disclosed in Form 8-K filed June 11, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.4,"calibrated_materiality_score":0.15,"market_cap_usd":101670000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157904,"accession_number":"0001654954-25-005749","cik":1684144,"company_name":"Zomedica Corp.","ticker":"ZOMDF","form_type":"8-K","filed_at":"2025-05-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zomedica Q1 revenue $6.5M (+4% YoY), net loss $63.8M on $55.8M impairment","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $6.5M (+4% YoY); gross margin 68% vs 66% in Q1 2024.","Net loss $63.8M includes $55.8M non-cash impairment from share price decline.","Adjusted EBITDA loss $5.7M vs $5.3M in Q1 2024; cash & securities $64.6M.","Consumables revenue up 13% to $4.5M; Diagnostics down 25% to $0.6M.","Shares outstanding 979.9M; liquidity down from $71.4M at Dec 31, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":6500000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":101670000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157903,"accession_number":"0001654954-25-004863","cik":1684144,"company_name":"Zomedica Corp.","ticker":"ZOMDF","form_type":"8-K","filed_at":"2025-04-30T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"CFO Scott Jordan resigns; VP Finance Michael Zuehlke assumes interim role","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Scott Jordan resigned as CFO effective April 25, 2025; receives $80,769 lump sum and 3 months COBRA reimbursement.","Michael Zuehlke (VP Finance and Corporate Controller) will handle accounting/finance operations until a permanent CFO is hired.","Mr. Jordan intends to return to his consulting firm S. Jordan Associates."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":101670000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176280,"accession_number":"0001654954-25-002744","cik":1684144,"company_name":"Zomedica Corp.","ticker":"ZOMDF","form_type":"8-K","filed_at":"2025-03-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zomedica reports record Q4 revenue $7.9M, full year $27.3M; net loss narrows to $7.2M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 revenue $7.9M (+8% YoY); full year $27.3M, also up 8% from 2023.","Gross margin 70.3% for Q4 and 70.0% for full year, at high end of 65-70% guidance.","Net loss improved to $7.2M in Q4 from $22.4M a year ago; full year net loss $47.0M vs $34.5M.","Diagnostics segment revenue surged 109% YoY in Q4 driven by TRUFORMA and VETGuardian adoption.","Cash, equivalents and securities $71.4M; adjusted non-GAAP EBITDA loss $20.2M for full year."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":101670000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176279,"accession_number":"0001654954-25-002296","cik":1684144,"company_name":"Zomedica Corp.","ticker":"ZOMDF","form_type":"8-K","filed_at":"2025-03-05T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"Zomedica delisted from NYSE American, to trade on OTCQB starting March 5 under ZOMDF","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["NYSE American suspended trading March 4, 2025 due to low share price under Section 1003(f)(v).","Company expects trading on OTCQB under symbol ZOMDF effective March 5, 2025.","CEO Larry Heaton stated disappointment but emphasized focus on growth and pipeline.","Company will continue to file periodic reports with the SEC and meet regulatory requirements.","Transition does not affect business or operations; real-time trading data remains available via OTC Markets."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":101670000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193168,"accession_number":"0001654954-24-015750","cik":1684144,"company_name":"Zomedica Corp.","ticker":"ZOMDF","form_type":"8-K","filed_at":"2024-12-19T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Zomedica appoints Scott Jordan as CFO effective Jan 1, 2025; base salary $350K plus options","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Scott Jordan appointed Executive VP Finance and CFO, effective January 1, 2025.","Jordan has over 30 years in life sciences/diagnostics; founded S. Jordan Associates.","Compensation includes $350K base salary, up to 40% bonus, 5M share options vesting over 4 years.","Succeeds Peter Donato, who departed as CFO in August 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":101670000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193167,"accession_number":"0001654954-24-014663","cik":1684144,"company_name":"Zomedica Corp.","ticker":"ZOMDF","form_type":"8-K","filed_at":"2024-11-19T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Zomedica enters new 15,371 sq ft lease for Ann Arbor HQ through Jan 2030","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Lease with 1101 Technology Drive, L.L.C. commences Feb 1, 2025, replacing prior lease.","Initial term ends Jan 31, 2030; two five-year renewal options on same terms.","Tenant pays utilities and proportionate share of expenses/taxes with 5% annual cap.","Base rent amount not disclosed in filing summary; full terms in Exhibit 10.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":101670000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193166,"accession_number":"0001654954-24-014016","cik":1684144,"company_name":"Zomedica Corp.","ticker":"ZOMDF","form_type":"8-K","filed_at":"2024-11-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zomedica Q3 revenue up 10% to $7.0M; gross margin 72.3%; diagnostics segment grows 38%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $7.0M (+10% YoY); gross margin 72.3% above 65-70% guidance.","Diagnostics segment revenue $0.5M (+38% YoY); Therapeutic Device $6.5M (+9%).","Net loss $6.7M vs $0.5M loss a year ago (prior year included $2.2M acquisition gain).","Adjusted non-GAAP EBITDA loss $4.3M; operating cash burn ~$5.2M, adjusted $4.0M.","Cash & securities $77.8M at Sept 30, down from $83.0M at June 30; no guidance change."],"consensus_eps_estimate":0.0,"consensus_eps_actual":-0.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":19390000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":101670000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209541,"accession_number":"0001654954-24-010666","cik":1684144,"company_name":"Zomedica Corp.","ticker":"ZOMDF","form_type":"8-K","filed_at":"2024-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zomedica reports record FY2023 revenue $25.2M (+33% YoY); net loss $34.5M; guides FY2024 $31-35M","summary_kind":"llm","event_type":"earnings","confidence":"medium","bullets":["Q4 2023 revenue $7.3M (+19% YoY); FY2023 revenue $25.2M (+33% YoY), driven by Diagnostics (+252%) and Therapeutic Devices (+28%).","Gross margin 69% for FY2023; consumable revenue $16.4M (+41% YoY), 65% of total revenue.","Net loss $34.5M ($0.035/share) vs $17.0M in FY2022; Adjusted Non-GAAP EBITDA loss $12.8M.","Cash and securities $100.5M at Dec 31, 2023; reiterated FY2024 revenue guidance $31-35M.","Acquisitions of SMP (VetGuardian) and Qorvo Biotechnologies in 2023; launched TRUVIEW and new assays."],"consensus_eps_estimate":0.0,"consensus_eps_actual":-0.034,"consensus_revenue_estimate":null,"consensus_revenue_actual":12393000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":101670000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209540,"accession_number":"0001654954-24-010665","cik":1684144,"company_name":"Zomedica Corp.","ticker":"ZOMDF","form_type":"8-K","filed_at":"2024-08-14T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Zomedica CFO Peter Donato resigns; VP Finance Zuehlke steps in as interim","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Peter Donato resigned effective Aug 15, 2024; enters 3-year consulting agreement for transition.","VP of Finance & Corporate Controller Michael Zuehlke assumes interim operational responsibility for accounting and finance.","Donato receives $20,312.50 flat fee for first 3 months (10 hrs/week) then $250/hr; 3-year consulting term.","Separation agreement includes mutual release, confidentiality, non-disparagement, and reimbursement of $27,500 for leased home.","Company conducting third-party search to replace Donato as CFO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":101670000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227633,"accession_number":"0001654954-24-007515","cik":1684144,"company_name":"Zomedica Corp.","ticker":"ZOMDF","form_type":"8-K","filed_at":"2024-06-07T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Zomedica shareholders reject advisory vote on executive compensation at 2024 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Advisory 'say-on-pay' resolution failed: 79,412,285 for vs. 88,436,460 against, plus 183,131,919 broker non-votes.","All eight director nominees elected; votes ranged from 103.6M to 117.6M for, with broker non-votes of ~183.1M.","Ratification of Grant Thornton LLP as auditor for 2024 passed: 288,330,513 for, 67,093,805 against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.45,"calibrated_materiality_score":0.15,"market_cap_usd":101670000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227632,"accession_number":"0001654954-24-005886","cik":1684144,"company_name":"Zomedica Corp.","ticker":"ZOMDF","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zomedica Q1 revenue up 14% to $6.3M, net loss widens to $9.2M; FY guidance reaffirmed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2024 revenue $6.3M (+14% YoY) driven by 86% growth in Diagnostics and 9% in Therapeutic Devices.","Net loss $9.2M ($0.01/share) vs $6.4M loss in Q1 2023; adjusted non-GAAP EBITDA loss $6.2M.","Gross margin 66%; consumable revenue $4.0M (64% of sales), capital revenue $2.2M (+30% YoY).","Cash and securities $90.9M at March 31, 2024, down from $100.5M at Dec 31, 2023.","FY 2024 revenue guidance maintained at $31-35M, up ~39% at high end from $25.2M in 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.009,"consensus_revenue_estimate":null,"consensus_revenue_actual":6262000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":101670000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227631,"accession_number":"0001654954-24-004239","cik":1684144,"company_name":"Zomedica Corp.","ticker":"ZOMDF","form_type":"8-K","filed_at":"2024-04-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zomedica reports record FY 2023 revenue $25.2M (+33% YoY); net loss $34.5M; guides FY 2024 revenue $31-35M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2023 revenue $7.3M (+19% YoY); full-year revenue $25.2M vs $18.9M in 2022.","Gross margin 69% for both Q4 and full year 2023; consumable revenue grew 41% to $16.4M.","Net loss $34.5M ($0.035 per share) vs $17.0M ($0.017) in 2022; adjusted non-GAAP EBITDA loss $12.8M.","Cash and securities $100.5M as of Dec 31, 2023; operating cash burn adjusted for one-time items ~$2.6M in Q4.","FY 2024 revenue guidance $31-35M (up to 40% YoY); growth driven by recent product launches and acquisitions."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.009,"consensus_revenue_estimate":null,"consensus_revenue_actual":6262000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":101670000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246429,"accession_number":"0001654954-24-003187","cik":1684144,"company_name":"Zomedica Corp.","ticker":"ZOMDF","form_type":"8-K","filed_at":"2024-03-15T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"Zomedica continues NYSE American listing dialogue after shareholder rejection of reverse split","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received NYSE American deficiency letter Sept 2023 for 30-day avg share price below $0.20 per Section 1003(f)(v).","Shareholders rejected proposed 80:1 reverse stock split at Feb 28, 2024 special meeting; 67.7% majority required.","Shares remain listed; exchange will monitor price and further deterioration could trigger delisting.","CEO Larry Heaton cites progress and opportunities to positively impact share price."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":101670000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246428,"accession_number":"0001654954-24-002358","cik":1684144,"company_name":"Zomedica Corp.","ticker":"ZOMDF","form_type":"8-K","filed_at":"2024-02-29T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Zomedica shareholders reject 80-for-1 reverse stock split at special meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Share Consolidation Proposal required two-thirds approval; received only 39.44% 'for' votes.","Final vote: 136,067,529 (39.44%) For, 206,789,223 (59.95%) Against, 2,109,080 (0.61%) Abstain.","Proposal not approved; company retains no shareholder authorization for reverse split.","The reverse split was likely intended to address NYSE American minimum bid price compliance.","Failure to approve may increase risk of delisting from NYSE American."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":101670000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}